Pharmaceuticals company Supriya Lifescience announced Q1FY26 results The company witnessed a 9.7% YoY decline in Revenue to Rs 145.07 crore compared to Rs 160.63 crore in Q1FY25. EBITDA for Q1FY26 stood at Rs. 51.70 crore, with an EBITDA margin of 35.6%, as against Rs 62.54 crore in Q1FY25 with a margin of 38.9%. The Profit After Tax (PAT) for Q1FY26 was Rs 34.79 crore, compared to RS 44.64 crore in Q1FY25. The PAT Margin stood at 24.0% in Q1FY26 versus 27.8% in Q1FY25. Anaesthetic segment led the revenue in Q1, contributing 53% to the revenue vs 45% in Q1FY25. European markets now contribute 41% of our business revenue in Q1FY26, up from 34% in Q1FY25. Satish Wagh, Chairman & Managing Director, Supriya Lifescience, said: “Our Q1 results reflect a temporary impact from the delay in the production facility campaign due to essential repair and maintenance at our Lote facility. These upgrades were critical to improving the efficiency of our older blocks and enabling full utilisation of Module E for upcoming product launches. Despite the revenue dip, EBITDA margins remained strong at 36%, backed by improved backwards integration and increased contribution from regulated markets. With the Ambernath site progressing towards commercial production in Q4, a strong pipeline of 3 to 4 product launches in FY26, and healthy demand across key therapeutic areas, we expect the second half to recover the delays from H1. We remain on track to deliver ~20% growth and reach Rs 1,000 crore revenue by FY27." Result PDF